IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer

J Virol. 2008 Apr;82(7):3632-41. doi: 10.1128/JVI.00599-07. Epub 2008 Jan 23.

Abstract

Human immunodeficiency virus type 1 (HIV-1) gene expression is controlled by a complex interplay between viral and host factors. We have previously shown that interferon-regulatory factor 1 (IRF-1) is stimulated early after HIV-1 infection and regulates promoter transcriptional activity even in the absence of the viral transactivator Tat. In this work we demonstrate that IRF-1 is also required for full NF-kappaB transcriptional activity. We provide evidence that IRF-1 and NF-kappaB form a functional complex at the long terminal repeat (LTR) kappaB sites, which is abolished by specific mutations in the two adjacent kappaB sites in the enhancer region. Silencing IRF-1 with small interfering RNA resulted in impaired NF-kappaB-mediated transcriptional activity and in repressed HIV-1 transcription early in de novo-infected T cells. These data indicate that in early phases of HIV-1 infection or during virus reactivation from latency, when the viral transactivator is absent or present at very low levels, IRF-1 is an additional component of the p50/p65 heterodimer binding the LTR enhancer, absolutely required for efficient HIV-1 replication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Cell Line
  • Electrophoretic Mobility Shift Assay
  • Gene Silencing
  • HIV Enhancer / genetics*
  • HIV Long Terminal Repeat / genetics*
  • HIV-1 / genetics
  • HIV-1 / physiology*
  • Humans
  • Immunoprecipitation
  • Interferon Regulatory Factor-1 / antagonists & inhibitors
  • Interferon Regulatory Factor-1 / metabolism*
  • NF-kappa B / metabolism*
  • Point Mutation
  • Protein Binding
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes / virology

Substances

  • Interferon Regulatory Factor-1
  • NF-kappa B